ScholarIQanswers from OpenAlex & ORCID
Rocio García‐Carbonero
ResearcherPublications, citations & collaboration network
Rocio García‐Carbonero is a researcher indexed in ScholarIQ from OpenAlex & ORCID.
How many works does Rocio García‐Carbonero have?
ScholarIQindexed works
Rocio García‐Carbonero has 590 works in the ScholarIQ index. The count is the OpenAlex total, not the number of papers listed on this page.
How many citations does Rocio García‐Carbonero have?
ScholarIQcitation count
Rocio García‐Carbonero has 20,242 citations in the OpenAlex counts ScholarIQ stores.
What is the h-index of Rocio García‐Carbonero?
ScholarIQh-index
Rocio García‐Carbonero has an h-index of 64 in OpenAlex.
What is the i10-index of Rocio García‐Carbonero?
ScholarIQi10-index
Rocio García‐Carbonero has an i10-index of 216 in OpenAlex.
What is the ORCID of Rocio García‐Carbonero?
ScholarIQorcid
The ORCID for Rocio García‐Carbonero is on the source record.
What is the OpenAlex record for Rocio García‐Carbonero?
ScholarIQopenalex
The OpenAlex for Rocio García‐Carbonero is on the source record.
What are the most-cited papers on Rocio García‐Carbonero?
ScholarIQmost cited works
Ramucirumab versus placebo in combination with second-line FOLFIRI in patients with metastatic colorectal carcinoma that progressed during or after first-line therapy with bevacizumab, oxaliplatin, and a fluoropyrimidine (RAISE): a randomised, double-blind, multicentre, phase 3 study
Josep Tabernero, Takayuki Yoshino, Allen Lee Cohn, Radka Obermannová, G. Bodoky, Rocio García‐Carbonero, Tudor–Eliade Ciuleanu, David C. Portnoy, Eric Van Cutsem, Axel Grothey, Jana Prausová, Pilar García‐Alfonso, Kentaro Yamazaki, Philip R. Clingan, Sara Lonardi, Tae Won Kim, Lorinda Simms, Shao-Chun Chang, Federico Nasroulah
ENETS Consensus Guidelines for High-Grade Gastroenteropancreatic Neuroendocrine Tumors and Neuroendocrine Carcinomas
Rocio García‐Carbonero, Halfdan Sørbye, Éric Baudin, Éric Raymond, Bertram Wiedenmann, Bruno Niederle, Eva Sedláčková, Christos Toumpanakis, Martin Anlauf, Jarosław B. Ćwikła, Martyn Caplin, Dermot O’Toole, Aurel Perren, all other Vienna Consensus Conference participants
Fruquintinib versus placebo in patients with refractory metastatic colorectal cancer (FRESCO-2): an international, multicentre, randomised, double-blind, phase 3 study
Arvind Dasari, Sara Lonardi, Rocio García‐Carbonero, Elena Élez, Takayuki Yoshino, Alberto Sobrero, James C. Yao, Pilar García‐Alfonso, Judit Kocsis, Antonio Cubillo Gracián, Andrea Sartore‐Bianchi, Taroh Satoh, Violaine Randrian, Jiří Tomášek, Geoff Chong, Andrew Scott Paulson, Toshiki Masuishi, Jeremy Jones, Tibor Csőszi, Chiara Cremolini, François Ghiringhelli, Ardaman Shergill, Howard S. Höchster, John C. Krauss, Ali Bassam, Michel Ducreux, Anneli Elme, Laurence Faugeras, Stefan Kasper, Eric Van Cutsem, Dirk Arnold, Shivani Nanda, Zhao Yang, William R. Schelman, Marek Kania, Josep Tabernero, Cathy Eng